Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;17(3):657-668.
doi: 10.1007/s12265-023-10457-8. Epub 2023 Nov 14.

Slow-Reflow and Prognosis in Patients with High Parathyroid Hormone Levels Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

Affiliations

Slow-Reflow and Prognosis in Patients with High Parathyroid Hormone Levels Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

Gangyong Wu et al. J Cardiovasc Transl Res. 2024 Jun.

Abstract

We aimed to evaluate the correlation among serum parathyroid hormone (PTH) and slow-reflow during primary percutaneous coronary intervention (PCI) and prognosis in patients with ST-segment elevation myocardial infarction (STEMI). A total of 262 patients were enrolled and divided into a slow-reflow group (n = 61) and a control group (n = 201). PTH was an independent risk factor for slow-reflow (P < 0.05), and the regression model had good discrimination and calibration. ROC curve analysis showed that PTH (≥ 63.65 pg/ml) had a predictive value for slow-reflow (P < 0.001). During the 1-year follow-up, the patients were divided into a PTH-h group (≥ 63.65 pg/ml, n = 100) and a PTH-l group (< 63.65 pg/ml, n = 162). Readmission for HF was independently associated with PTH levels (P < 0.05). KM survival analysis suggested that PTH-h had a predictive value for MACEs, especially for readmission for HF (P < 0.05). PTH levels were associated with slow-reflow during PCI and MACEs during follow-up in patients with STEMI.

Keywords: Acute ST-segment elevation myocardial infarction; Major adverse cardiovascular events; Parathyroid hormone; Percutaneous coronary intervention; Prognosis; Slow-reflow.

PubMed Disclaimer

Similar articles

References

    1. Gao G, Xu H, Zhang D, Song C, Guan C, Xu B, et al. The predictive value of baseline target lesion SYNTAX score for no-reflow during urgent percutaneous coronary intervention in acute myocardial infarction. J Interv Cardiol. 2021;2021:9987265. https://doi.org/10.1155/2021/9987265 . - DOI - PubMed - PMC
    1. Tasar O, Karabay AK, Oduncu V, Kirma C. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2019;30(4):270–6. https://doi.org/10.1097/MCA.0000000000000726 . - DOI - PubMed
    1. Niu X, Zhang J, Bai M, Peng Y, Sun S, Zhang Z. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis. BMC Cardiovasc Disord. 2018;18(1):3. https://doi.org/10.1186/s12872-017-0722-z . - DOI - PubMed - PMC
    1. Isaksson E, Almquist M, Seeberger A, Sterner G. Is low pre-transplant parathyroid hormone a risk marker for cardiovascular disease in long-term follow-up of renal transplant recipients? Clin Exp Nephrol. 2018;22(5):1188–97. https://doi.org/10.1007/s10157-018-1543-9 . - DOI - PubMed - PMC
    1. Radhakrishnan A, Pickup LC, Price AM, Law JP, Edwards NC, Steeds RP, et al. Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy? Heart. 2019;105(17):1302–9. https://doi.org/10.1136/heartjnl-2019-315138 . - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources